Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]
Leticia Orsatti, Josep Fortea, Manuel Quaresma Boehringer Ingelheim International GmbH, Ingelheim, GermanyWe read with interest the study by Abe et al on the clinical utility of nintedanib in patients with severe idiopathic pulmonary fibrosis (IPF).1 Based on the retrospective fol...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-04-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/letter-utility-of-nintedanib-for-severe-idiopathic-pulmonary-fibr-peer-reviewed-article-DDDT |
| _version_ | 1818557512732901376 |
|---|---|
| author | Orsatti L Fortea J Quaresma M |
| author_facet | Orsatti L Fortea J Quaresma M |
| author_sort | Orsatti L |
| collection | DOAJ |
| description | Leticia Orsatti, Josep Fortea, Manuel Quaresma Boehringer Ingelheim International GmbH, Ingelheim, GermanyWe read with interest the study by Abe et al on the clinical utility of nintedanib in patients with severe idiopathic pulmonary fibrosis (IPF).1 Based on the retrospective follow-up of 51 patients, the authors concluded that the survival benefit from nintedanib is reduced among patients with severe IPF (n=17) compared with those with mild-to-moderate IPF (n=34), but that the prognosis for patients with severe IPF is significantly better in those who remain on nintedanib for more than 3 months.In our opinion, the study design does not allow conclusions to be drawn about the treatment effect of nintedanib on survival in patients with severe versus mild-tomoderate IPF.View the original paper by Abe and colleagues |
| first_indexed | 2024-12-14T00:00:29Z |
| format | Article |
| id | doaj.art-800e0135075a4ed3b187ac3f8b4ffa17 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-14T00:00:29Z |
| publishDate | 2019-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-800e0135075a4ed3b187ac3f8b4ffa172022-12-21T23:26:22ZengDove Medical PressDrug Design, Development and Therapy1177-88812019-04-01Volume 131177117845118Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]Orsatti LFortea JQuaresma MLeticia Orsatti, Josep Fortea, Manuel Quaresma Boehringer Ingelheim International GmbH, Ingelheim, GermanyWe read with interest the study by Abe et al on the clinical utility of nintedanib in patients with severe idiopathic pulmonary fibrosis (IPF).1 Based on the retrospective follow-up of 51 patients, the authors concluded that the survival benefit from nintedanib is reduced among patients with severe IPF (n=17) compared with those with mild-to-moderate IPF (n=34), but that the prognosis for patients with severe IPF is significantly better in those who remain on nintedanib for more than 3 months.In our opinion, the study design does not allow conclusions to be drawn about the treatment effect of nintedanib on survival in patients with severe versus mild-tomoderate IPF.View the original paper by Abe and colleagueshttps://www.dovepress.com/letter-utility-of-nintedanib-for-severe-idiopathic-pulmonary-fibr-peer-reviewed-article-DDDTNintedanibsevere idiopathic pulmonary fibrosisprognosissurvivalreal-world |
| spellingShingle | Orsatti L Fortea J Quaresma M Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter] Drug Design, Development and Therapy Nintedanib severe idiopathic pulmonary fibrosis prognosis survival real-world |
| title | Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter] |
| title_full | Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter] |
| title_fullStr | Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter] |
| title_full_unstemmed | Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter] |
| title_short | Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter] |
| title_sort | utility of nintedanib for severe idiopathic pulmonary fibrosis a single center retrospective study letter |
| topic | Nintedanib severe idiopathic pulmonary fibrosis prognosis survival real-world |
| url | https://www.dovepress.com/letter-utility-of-nintedanib-for-severe-idiopathic-pulmonary-fibr-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT orsattil utilityofnintedanibforsevereidiopathicpulmonaryfibrosisasinglecenterretrospectivestudyletter AT forteaj utilityofnintedanibforsevereidiopathicpulmonaryfibrosisasinglecenterretrospectivestudyletter AT quaresmam utilityofnintedanibforsevereidiopathicpulmonaryfibrosisasinglecenterretrospectivestudyletter |